Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.

Breast cancer research and treatment - 1 Jan 2012

Hein R, Abbas S, Seibold P, Salazar R, Flesch-Janys D, Chang-Claude J

Abstract excerpt

Menopausal hormone therapy (MHT) is associated with an increased breast cancer risk in postmenopausal women, with combined estrogen-progestagen therapy posing a greater risk than estrogen monotherapy. However, few studies focused on potential effect modification of MHT-associated breast cancer risk by genetic polymorphisms in the progesterone metabolism. We assessed effect modification of MHT use by five coding...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Hormone Replacement Therapy

Share to Membrane Proteins

Share to Postmenopause

Share to Progesterone

Share to Risk Factors

Source

Identifiers

PMID: 21947678
DOI: 10.1007/s10549-011-1772-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Polymorphism Thr160Thr in SRD5A1, involved in the progesterone metabolism, modifies postmenopausal breast cancer risk associated with menopausal hormone therapy.PMID 21947678Read ↗

Genetic variation in the progesterone receptor and metabolism pathways and hormone therapy in relation to breast cancer risk.Semantic proximity Read ↗

Progesterone Receptor Gene Polymorphisms and Breast Cancer Risk.Semantic proximity Read ↗

Polymorphisms in the BRCA1 and ABCB1 genes modulate menopausal hormone therapy associated breast cancer risk in postmenopausal women.Semantic proximity Read ↗

Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy.Semantic proximity Read ↗

Progesterone Receptor (PGR) Gene Variants Associated with Breast Cancer and Associated Features: a Case-Control Study.Semantic proximity Read ↗

Postmenopausal estrogen monotherapy-associated breast cancer risk is modified by CYP17A1_-34_T>C polymorphism.Semantic proximity Read ↗

A genome-wide association study to identify genetic susceptibility loci that modify ductal and lobular postmenopausal breast cancer risk associated with menopausal hormone therapy use: a two-stage design with replication.Semantic proximity Read ↗

Progesterone receptor gene variants and risk of endometrial cancer.Semantic proximity Read ↗

+331G/A variant in the progesterone receptor gene, postmenopausal hormone use and risk of breast cancer.Semantic proximity Read ↗

Hormone-related pathways and risk of breast cancer subtypes in African American women.Semantic proximity Read ↗

Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.Semantic proximity Read ↗

Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.